Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXGD +5.08%41 Earnings per Share (Diluted) is $4.45 as of Jun. 2026. GuruFocus rates IDXGD with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, Interpace Biosciences ranks worse than 632910.76% on this metric.
During the past 13 years, Interpace Biosciences's highest 3-Year average EPS without NRI Growth Rate was 70.30% per year. The lowest was -103.10% per year. And the median was 14.80% per year.
Interpace Biosciences (OTCPK:IDXGD) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Interpace Biosciences Earnings per Share (Diluted) Related Terms
Interpace Biosciences Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences Earnings per Share (Diluted) Chart
IDXGD vs PRPO, ADVB, BIOQ: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's PE Ratio falls into.
Interpace Biosciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Interpace Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $4.45 mean?
Interpace Biosciences (IDXGD) has a Earnings per Share (Diluted) of $4.45 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #999999 out of 158 companies in the Medical Diagnostics & Research industry.
Is Interpace Biosciences' Earnings per Share (Diluted) too high?
Interpace Biosciences' current Earnings per Share (Diluted) is $4.45. The Medical Diagnostics & Research industry median Earnings per Share (Diluted) is 10.75. Interpace Biosciences' value of $4.45 is 58.6% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #999999 out of 158 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Earnings per Share (Diluted) compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #999999 out of 158 companies for Earnings per Share (Diluted). This places Interpace Biosciences in the lower half of its industry. The industry median Earnings per Share (Diluted) is 10.75. Interpace Biosciences' value of $4.45 is 58.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Earnings per Share (Diluted) of $4.45 is 58.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Earnings per Share (Diluted) is $4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXGD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $7.62 — trading 3709% above its estimated fair value. The current Earnings per Share (Diluted) is $4.45 and 58.6% below the Medical Diagnostics & Research industry median of 10.75. Interpace Biosciences' overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Interpace Biosciences (IDXGD), the current Earnings per Share (Diluted) is $4.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXGD) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $7.62 is trading 3709% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXGD:
Earnings per Share (Diluted): $4.45
GF Value™: $0.20 vs. price of $7.62 (3709% above fair value)
Industry Position: 58.6% below the Medical Diagnostics & Research median (#999999 of 158)
No single metric tells the full story. See the IDXGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXGD
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXGD has been successfully added to your 
